Stockscreener 앱 받기
38.22
0.91%
-0.35
시간 외 거래:
38.00
-0.22
-0.58%
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO Stock News - GuruFocus
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - ADVFN
Cantor Fitzgerald Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2025 Earnings Call Transcript - Insider Monkey
High Growth Tech Stocks In The US Market May 2025 - simplywall.st
BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
Excellent Earnings Propelled Prices of These 10 Firms - Insider Monkey
BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales - insights.citeline.com
Decoding BridgeBio Pharma Inc (BBIO): A Strategic SWOT Insight - GuruFocus
BridgeBio sales of new heart drug outstrip expectations - BioPharma Dive
BridgeBio (BBIO) Price Target Increased by Scotiabank Analyst | - GuruFocus
Attruby's Momentum and an Advancing Pipeline Support BridgeBio's Long-Term Growth Outlook - Morningstar
UBS Raises Price Target for BridgeBio (BBIO) Amid Strong Q1 Perf - GuruFocus
UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating - marketscreener.com
Scotiabank raises BridgeBio stock target to $55 on strong sales By Investing.com - Investing.com India
BridgeBio (BBIO) Price Target Uplifted by BofA Analyst Amid Stro - GuruFocus
Scotiabank raises BridgeBio stock target to $55 on strong sales - Investing.com
BridgeBio price target raised to $63 from $46 at Piper Sandler - TipRanks
BridgeBio (BBIO) Target Price Increased by Piper Sandler Followi - GuruFocus
BridgeBio (BBIO) Target Price Increased by Piper Sandler Following Strong Quarter | BBIO Stock News - GuruFocus
BridgeBio’s Attruby outperforms sales expectations, shares rise - Endpoints News
BridgeBio Pharma’s Attruby Outperforms Expectations, Analyst Raises Price Target to $50 - TipRanks
(BBIO) Trading Advice - news.stocktradersdaily.com
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: St - GuruFocus
BridgeBio Pharma: Q1 Earnings Snapshot - CT Insider
BridgeBio Pharma Reports Q1 2025 Earnings and Pipeline Progress - TipRanks
Earnings call transcript: BridgeBio Q1 2025 shows strong revenue growth By Investing.com - Investing.com Nigeria
Earnings call transcript: BridgeBio Q1 2025 shows strong revenue growth - Investing.com
BridgeBio Pharma, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma (BBIO) Reports Strong Q1 Earnings, Shares Rise - GuruFocus
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
BridgeBio Pharma Q1 Loss Widens, Revenue Drops - marketscreener.com
BridgeBio (BBIO) Exceeds Revenue Expectations with Strong Prescr - GuruFocus
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates - The Manila Times
BridgeBio Reports Blockbuster Q1: New Drug Attruby Surges with 2,072 Patient Scripts, Pipeline Advances - Stock Titan
BridgeBio (BBIO) Anticipates Significant Post-Earnings Volatilit - GuruFocus
BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - MSN
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM - Yahoo
BridgeBio Pharma (BBIO) Set to Release Q1 Earnings Report - GuruFocus
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: Wha - GuruFocus
A Look Ahead: BridgeBio Pharma's Earnings Forecast - Benzinga
Transthyretin Amyloid Cardiomyopathy Treatment Market Size - openPR.com
Pinning Down BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) P/S Is Difficult Right Now - simplywall.st
BridgeBio (BBIO) Gains UK Approval for Cardiomyopathy Drug | BBI - GuruFocus
BridgeBio Pharma's Beyonttra Approved in UK for Heart Condition due to Amyloidosis - marketscreener.com
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer - GuruFocus
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM - The Globe and Mail
BridgeBio announces UK MHRA marketing authorization for acoramidis - TipRanks
BridgeBio Pharma Receives UK Approval for BEYONTTRA® (acoramidis) to Treat ATTR-CM - Nasdaq
UK Approves Groundbreaking ATTR-CM Drug BEYONTTRA with 42% Mortality Benefit | BBIO Stock News - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update - ADVFN
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - ADVFN
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO) - PrimePublishers.com
0.39%
3.66%
자본화:
|
볼륨(24시간):